

**BLAU FARMACÊUTICA S.A.**

Publicly Held Corporation

CNPJ/MF 58.430.828/0001-60

NIRE 35.300.416.406

CVM Code 2462-7

**NOTICE TO THE MARKET****Blau receives FDA authorization to use plasma from its 1st Center**

**BLAU FARMACÊUTICA S.A.** ("Blau" or "Company"), one of the main Brazilian pharmaceutical companies in Latin America focused on the production of highly complex medicines for the institutional segment, announces that Hemarus Plasma - JV of the plasma collection center in the United States - obtained authorization of the BLA (Biologic License Application) by FDA (US Food and Drug Administration). With this achievement, the plasma collected at its 1st center in Lauderhill - Florida can now be used to manufacture injectable and non-injectable products. The plasma collection in this center started in June 2021 and currently collects a volume of approximately 25% of its total capacity. We have already expanded opening hours and we are increasing the number of donors every day.

"The approval of this plasma collection center represents another milestone for Blau, it is an important step in the execution of our verticalization strategy. We continue with our mission to expand access to drugs and products for unmet medical needs.", says Marcelo Hahn, CEO of Blau.

Now, with this approval, the Lauderhill Center is licensed by the FDA for the use of human source plasma in the United States for drug production. Blau remains focused on the expansion of this business and the opening of the next plasma collection centers.

Cotia, December 15th, 2021.

Melissa Angelini

Investors Relation Officer

**About Blau Farmacêutica:**

Blau is a leading pharmaceutical industry in the institutional segment and a pioneer in biotechnology, with an owned brands portfolio of highly complex drugs focused on relevant segments in the industry, such as immunology, hematology, oncology, specialties, antibiotics in various classes, among others.

Blau has a continental footprint, present in 6 countries in Latin America and the United States and has a modern pharmaceutical industrial complex, composed of four industrial plants, with cutting-edge technology, dedicated to the production of biological, biotechnological, oncological, antibiotic, anesthetic drugs injectables and biotechnological ingredients.